Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 3/2017

01-12-2017

Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis

Authors: Francois Chasset, Camille Francès

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2017

Login to get access

Abstract

Dermatologic manifestations are observed in almost all systemic vasculitides, even in large-and medium-vessel vasculitides, although such vessels are not found in the skin. Cutaneous manifestations may be related to a direct skin localization of the systemic vasculitis or a non-specific process associated with the vasculitis. According to the 2012 International Chapel Hill consensus, the two major variants of large-vessel vasculitides are Takayasu arteritis and giant-cell arteritis. In Europe and North America, acute inflammatory nodules or erythema nodosum-like lesions are the most commonly observed skin lesions with Takayasu arteritis. Medium-sized arteriole vasculitis of the dermis or subcutis but also septal or lobular panniculitis may be found during pathological examination. In Japan, widespread pyoderma gangrenosum-like lesions are more frequent. Cutaneous manifestations of giant-cell arteritis are rare; they are ischemic, linked to arterial occlusions, or non-ischemic, with various mechanisms. The two major medium-vessel vasculitides are Kawasaki disease and polyarteritis nodosa. Kawasaki disease is characterized by a mucocutaneous lymph node syndrome without skin vasculitis. Two subsets of polyarteritis nodosa with different skin manifestations are described, without transition from one to the other. In the systemic subset, the most frequent skin lesions are in the order of frequency purpura, livedo, and nodules. Cutaneous polyarteritis nodosa mainly features nodules, livedo racemosa, and ulcerations. Genetic screening and measurement of plasma levels of adenosine deaminase 2 should be considered for patients with uncommon systemic polyarteritis nodosa or early-onset cutaneous polyarteritis nodosa.
Literature
4.
go back to reference Gudbrandsson B, Molberg Ø, Garen T, Palm Ø (2017) Prevalence, incidence, and disease characteristics of Takayasu arteritis by ethnic background: data from a large, population-based cohort resident in southern Norway. Arthritis Care Res 69:278–285. doi:10.1002/acr.22931 CrossRef Gudbrandsson B, Molberg Ø, Garen T, Palm Ø (2017) Prevalence, incidence, and disease characteristics of Takayasu arteritis by ethnic background: data from a large, population-based cohort resident in southern Norway. Arthritis Care Res 69:278–285. doi:10.​1002/​acr.​22931 CrossRef
7.
go back to reference Shelhamer JH, Volkman DJ, Parrillo JE et al (1985) Takayasu’s arteritis and its therapy. Ann Intern Med 103:121–126CrossRefPubMed Shelhamer JH, Volkman DJ, Parrillo JE et al (1985) Takayasu’s arteritis and its therapy. Ann Intern Med 103:121–126CrossRefPubMed
9.
go back to reference Perniciaro CV, Winkelmann RK, Hunder GG (1987) Cutaneous manifestations of Takayasu’s arteritis. A clinicopathologic correlation. J Am Acad Dermatol 17:998–1005CrossRefPubMed Perniciaro CV, Winkelmann RK, Hunder GG (1987) Cutaneous manifestations of Takayasu’s arteritis. A clinicopathologic correlation. J Am Acad Dermatol 17:998–1005CrossRefPubMed
10.
go back to reference Perniciaro C, Winkelmann RK (1986) Cutaneous extravascular necrotizing granuloma in a patient with Takayasu’s aortitis. Arch Dermatol 122:201–204CrossRefPubMed Perniciaro C, Winkelmann RK (1986) Cutaneous extravascular necrotizing granuloma in a patient with Takayasu’s aortitis. Arch Dermatol 122:201–204CrossRefPubMed
11.
go back to reference Francès C, Boisnic S, Blétry O et al (1990) Cutaneous manifestations of Takayasu arteritis. A retrospective study of 80 cases. Dermatologica 181:266–272CrossRefPubMed Francès C, Boisnic S, Blétry O et al (1990) Cutaneous manifestations of Takayasu arteritis. A retrospective study of 80 cases. Dermatologica 181:266–272CrossRefPubMed
12.
go back to reference Kaditis AG, Nelson AM, Driscoll DJ (1995) Takayasu’s arteritis presenting with unilateral digital clubbing. J Rheumatol 22:2346–2348PubMed Kaditis AG, Nelson AM, Driscoll DJ (1995) Takayasu’s arteritis presenting with unilateral digital clubbing. J Rheumatol 22:2346–2348PubMed
13.
go back to reference Pascual-López M, Hernández-Núñez A, Aragüés-Montañés M et al (2004) Takayasu’s disease with cutaneous involvement. Dermatol Basel Switz 208:10–15. doi:10.1159/000075039 CrossRef Pascual-López M, Hernández-Núñez A, Aragüés-Montañés M et al (2004) Takayasu’s disease with cutaneous involvement. Dermatol Basel Switz 208:10–15. doi:10.​1159/​000075039 CrossRef
14.
go back to reference Skaria AM, Ruffieux P, Piletta P, et al (2000) Takayasu arteritis and cutaneous necrotizing vasculitis. Dermatol Basel Switz 200:139–143. doi: 18348 Skaria AM, Ruffieux P, Piletta P, et al (2000) Takayasu arteritis and cutaneous necrotizing vasculitis. Dermatol Basel Switz 200:139–143. doi: 18348
15.
go back to reference Mousa AR, Marafie AA, Dajani AI (1985) Cutaneous necrotizing vasculitis complicating Takayasu’s arteritis with a review of cutaneous manifestations. J Rheumatol 12:607–610PubMed Mousa AR, Marafie AA, Dajani AI (1985) Cutaneous necrotizing vasculitis complicating Takayasu’s arteritis with a review of cutaneous manifestations. J Rheumatol 12:607–610PubMed
20.
go back to reference Werfel T, Kuipers JG, Zeidler H et al (1996) Cutaneous manifestations of Takayasu arteritis. Acta Derm Venereol 76:496–497PubMed Werfel T, Kuipers JG, Zeidler H et al (1996) Cutaneous manifestations of Takayasu arteritis. Acta Derm Venereol 76:496–497PubMed
22.
go back to reference Hoffman GS, Leavitt RY, Kerr GS et al (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582CrossRefPubMed Hoffman GS, Leavitt RY, Kerr GS et al (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582CrossRefPubMed
25.
go back to reference Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol Hoboken NJ. doi:10.1002/art.40037 Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol Hoboken NJ. doi:10.​1002/​art.​40037
26.
go back to reference Catanoso M, Macchioni P, Boiardi L et al (2017) Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res 69:430–438. doi:10.1002/acr.22942 CrossRef Catanoso M, Macchioni P, Boiardi L et al (2017) Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res 69:430–438. doi:10.​1002/​acr.​22942 CrossRef
28.
go back to reference Liozon E, Herrmann F, Ly K et al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111:211–217CrossRefPubMed Liozon E, Herrmann F, Ly K et al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111:211–217CrossRefPubMed
30.
go back to reference Hitch JM (1970) Dermatologic manifestations of giant-cell (temporal, cranial) arteritis. Arch Dermatol 101:409–415CrossRefPubMed Hitch JM (1970) Dermatologic manifestations of giant-cell (temporal, cranial) arteritis. Arch Dermatol 101:409–415CrossRefPubMed
31.
go back to reference Kinmont PD, Mccallum DI (1964) Skin manifestations of giant-cell arteritis. Br J Dermatol 76:299–308CrossRefPubMed Kinmont PD, Mccallum DI (1964) Skin manifestations of giant-cell arteritis. Br J Dermatol 76:299–308CrossRefPubMed
32.
go back to reference Currey J (1997) Scalp necrosis in giant cell arteritis and review of the literature. Br J Rheumatol 36:814–816CrossRefPubMed Currey J (1997) Scalp necrosis in giant cell arteritis and review of the literature. Br J Rheumatol 36:814–816CrossRefPubMed
34.
go back to reference Vegesack EC, Fick S, Czarnecka A et al (2015) Successful wound closure using artificial dermis and split-skin grafting in deep bilateral scalp necrosis caused by giant cell arteritis. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 13:591–593. doi:10.1111/ddg.12558 CrossRef Vegesack EC, Fick S, Czarnecka A et al (2015) Successful wound closure using artificial dermis and split-skin grafting in deep bilateral scalp necrosis caused by giant cell arteritis. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 13:591–593. doi:10.​1111/​ddg.​12558 CrossRef
35.
go back to reference Hansen BL, Junker P (1995) Giant cell arteritis presenting with ischaemic skin lesions of the neck. Br J Rheumatol 34:1182–1184CrossRefPubMed Hansen BL, Junker P (1995) Giant cell arteritis presenting with ischaemic skin lesions of the neck. Br J Rheumatol 34:1182–1184CrossRefPubMed
36.
go back to reference Greene GM, Lain D, Sherwin RM et al (1986) Giant cell arteritis of the legs. Clinical isolation of severe disease with gangrene and amputations. Am J Med 81:727–733CrossRefPubMed Greene GM, Lain D, Sherwin RM et al (1986) Giant cell arteritis of the legs. Clinical isolation of severe disease with gangrene and amputations. Am J Med 81:727–733CrossRefPubMed
37.
go back to reference Letellier P, Andres L, Dassonville L, Gires C, Zoulim A, Compère JF et al (2000) Manifestations ORL et stomatologiques de la maladie de Horton. Etude prospective de 1980 à 2000 portant sur 250 malades. Rev Med Interne 21:485–486CrossRef Letellier P, Andres L, Dassonville L, Gires C, Zoulim A, Compère JF et al (2000) Manifestations ORL et stomatologiques de la maladie de Horton. Etude prospective de 1980 à 2000 portant sur 250 malades. Rev Med Interne 21:485–486CrossRef
40.
go back to reference Yáñez S, Val-Bernal JF, Peña-Sagredo JL et al (2008) Generalized granuloma annulare and giant cell arteritis. Clin Exp Rheumatol 26:S108–S110PubMed Yáñez S, Val-Bernal JF, Peña-Sagredo JL et al (2008) Generalized granuloma annulare and giant cell arteritis. Clin Exp Rheumatol 26:S108–S110PubMed
42.
go back to reference Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318. doi:10.1002/art.10262 CrossRefPubMed Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318. doi:10.​1002/​art.​10262 CrossRefPubMed
43.
go back to reference Villiger PM, Adler S, Kuchen S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 387:1921–1927. doi:10.1016/S0140-6736(16)00560-2 CrossRef Villiger PM, Adler S, Kuchen S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 387:1921–1927. doi:10.​1016/​S0140-6736(16)00560-2 CrossRef
44.
go back to reference Newburger JW, Takahashi M, Gerber MA et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708–1733. doi:10.1542/peds.2004-2182 CrossRefPubMed Newburger JW, Takahashi M, Gerber MA et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708–1733. doi:10.​1542/​peds.​2004-2182 CrossRefPubMed
52.
go back to reference Kumar S, Vaidyanathan B, Gayathri S, Rajam L (2013) Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review. Rheumatol Int 33:1065–1069. doi:10.1007/s00296-010-1650-8 CrossRefPubMed Kumar S, Vaidyanathan B, Gayathri S, Rajam L (2013) Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review. Rheumatol Int 33:1065–1069. doi:10.​1007/​s00296-010-1650-8 CrossRefPubMed
57.
go back to reference Kussmaul A, Maier K (1866) Ueber eine nicht bisher beschriebene eigenhümliche Arterienerkrankung (Periarteritis Nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1:484–518 Kussmaul A, Maier K (1866) Ueber eine nicht bisher beschriebene eigenhümliche Arterienerkrankung (Periarteritis Nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1:484–518
59.
go back to reference Daoud MS, Hutton KP, Gibson LE (1997) Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol 136:706–713CrossRefPubMed Daoud MS, Hutton KP, Gibson LE (1997) Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol 136:706–713CrossRefPubMed
62.
go back to reference Buffiere-Morgado A, Battistella M, Vignon-Pennamen M-D et al (2015) Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): blinded histologic assessment of 35 cPAN cases. J Am Acad Dermatol 73:1013–1020. doi:10.1016/j.jaad.2015.09.010 CrossRefPubMed Buffiere-Morgado A, Battistella M, Vignon-Pennamen M-D et al (2015) Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): blinded histologic assessment of 35 cPAN cases. J Am Acad Dermatol 73:1013–1020. doi:10.​1016/​j.​jaad.​2015.​09.​010 CrossRefPubMed
65.
go back to reference de Menthon M, Mahr A (2011) Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 29:S110–S116PubMed de Menthon M, Mahr A (2011) Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 29:S110–S116PubMed
66.
go back to reference Pagnoux C, Seror R, Henegar C et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616–626. doi:10.1002/art.27240 CrossRefPubMed Pagnoux C, Seror R, Henegar C et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616–626. doi:10.​1002/​art.​27240 CrossRefPubMed
67.
go back to reference Lightfoot RW, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088–1093CrossRefPubMed Lightfoot RW, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088–1093CrossRefPubMed
69.
go back to reference Henegar C, Pagnoux C, Puéchal X et al (2008) A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum 58:1528–1538. doi:10.1002/art.23470 CrossRefPubMed Henegar C, Pagnoux C, Puéchal X et al (2008) A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum 58:1528–1538. doi:10.​1002/​art.​23470 CrossRefPubMed
70.
go back to reference Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227. doi:10.1136/ard.2006.054593 CrossRefPubMed Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227. doi:10.​1136/​ard.​2006.​054593 CrossRefPubMed
71.
go back to reference Gocke DJ, Hsu K, Morgan C et al (1970) Association between polyarteritis and Australia antigen. Lancet Lond Engl 2:1149–1153CrossRef Gocke DJ, Hsu K, Morgan C et al (1970) Association between polyarteritis and Australia antigen. Lancet Lond Engl 2:1149–1153CrossRef
73.
go back to reference Pagnoux C, Cohen P, Guillevin L (2006) Vasculitides secondary to infections. Clin Exp Rheumatol 24:S71–S81PubMed Pagnoux C, Cohen P, Guillevin L (2006) Vasculitides secondary to infections. Clin Exp Rheumatol 24:S71–S81PubMed
75.
go back to reference Blétry O, Godeau P, Charpentier G et al (1980) Cardiac manifestations of periarteritis nodosa. Incidence of non-hypertensive cardiomyopathy. Arch Mal Coeur Vaiss 73:1027–1036PubMed Blétry O, Godeau P, Charpentier G et al (1980) Cardiac manifestations of periarteritis nodosa. Incidence of non-hypertensive cardiomyopathy. Arch Mal Coeur Vaiss 73:1027–1036PubMed
76.
go back to reference Cacoub P, Null LTH, Guillevin L, Godeau P (1988) Causes of death in systemic vasculitis of polyarteritis nodosa. Analysis of a series of 165 patients. Ann Med Interne (Paris) 139:381–390 Cacoub P, Null LTH, Guillevin L, Godeau P (1988) Causes of death in systemic vasculitis of polyarteritis nodosa. Analysis of a series of 165 patients. Ann Med Interne (Paris) 139:381–390
79.
go back to reference Akova YA, Jabbur NS, Foster CS (1993) Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. Ophthalmology 100:1775–1781CrossRefPubMed Akova YA, Jabbur NS, Foster CS (1993) Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. Ophthalmology 100:1775–1781CrossRefPubMed
81.
go back to reference Guillevin L, Pagnoux C, Seror R et al (2011) The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19–27. doi:10.1097/MD.0b013e318205a4c6 CrossRef Guillevin L, Pagnoux C, Seror R et al (2011) The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19–27. doi:10.​1097/​MD.​0b013e318205a4c6​ CrossRef
83.
go back to reference Gayraud M, Guillevin L, Cohen P et al (1997) Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 36:1290–1297CrossRefPubMed Gayraud M, Guillevin L, Cohen P et al (1997) Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 36:1290–1297CrossRefPubMed
84.
go back to reference Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol Hoboken NJ 67:1117–1127. doi:10.1002/art.39011 CrossRef Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol Hoboken NJ 67:1117–1127. doi:10.​1002/​art.​39011 CrossRef
87.
go back to reference Soufir N, Descamps V, Crickx B et al (1999) Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases. Arch Dermatol 135:1001–1002CrossRefPubMed Soufir N, Descamps V, Crickx B et al (1999) Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases. Arch Dermatol 135:1001–1002CrossRefPubMed
91.
go back to reference Mimouni D, Ng PP, Rencic A et al (2003) Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol 148:789–794CrossRefPubMed Mimouni D, Ng PP, Rencic A et al (2003) Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol 148:789–794CrossRefPubMed
98.
go back to reference Nanthapisal S, Murphy C, Omoyinmi E et al (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol Hoboken NJ 68:2314–2322. doi:10.1002/art.39699 CrossRef Nanthapisal S, Murphy C, Omoyinmi E et al (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol Hoboken NJ 68:2314–2322. doi:10.​1002/​art.​39699 CrossRef
Metadata
Title
Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis
Authors
Francois Chasset
Camille Francès
Publication date
01-12-2017
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2017
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-017-8612-9

Other articles of this Issue 3/2017

Clinical Reviews in Allergy & Immunology 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine